Strategic Initiative

Slingshot members are tracking this corporate initiative:

Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details As previously announced, Merck will be responsible for all future product development expenses for the selected antibody candidate and Agenus is eligible to receive up to $100 million in milestone payments, as well as royalties on worldwide product sales.“We are pleased that in collaboration with Merck scientists, our research team has successfully identified antibody candidates to advance into preclinical studies,” said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. “This is an important validation of our discovery platform and expertise and adds to our successes in discovering antibodies for a broad range of targets, including challenging ones.”“Our integrated monoclonal antibody discovery platforms have successfully identified unique antibodies for a wide range of therapeutic targets,” said Robert B. Stein, M.D., Ph.D., Agenus’ President, Research & Development. “This discovery engine provides Agenus the opportunity to bring innovative single-agent and combination immuno-oncology therapies to patients whose cancers are not adequately treated with current approaches.”
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jun 09, 2016
Projected Implementation:
Q2, 2016
Relevance Tracked Until:
Q3, 2016
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Antibody Candidate